Earnings Call · Q1 FY2026·2025-11-13

Q1 26EPS +52.63%·Rev n/aQ4 25EPS -100.00%*·Rev n/aQ3 25EPS +100.00%*·Rev n/aQ2 25EPS +100.00%*·Rev n/a⚠ consensus missing

AYTU BIOPHARMA, INC AYTU

Robert Blum — Investor Relations

Joshua Disbrow — Chief Executive Officer

Ryan J. Selhorn — Chief Financial Officer

+1.5%1d on move date+1.5% vs SPY3d−1.9%5d−5.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AYTU calls or request research access.

More AYTU calls Browse calls Request research access